Osteopore (ASX:OSX) share price rockets 24% on major new deal

This healthcare company is having a good day on the ASX today

The Osteopore Ltd (ASX: OSX) share price is surging today after the company announced it has signed a new research deal.

The medical technology company's share price soared 33% higher to 28 cents in early trading, before retreating slightly to 26 cents apiece at the time of writing. That's still 23.81% higher than the previous closing price.

Osteopore engineers and commercialises products that regenerate the tissues in the bones.

Three healthcare workers look and point at at medical image

Image source: Getty Images

What did the company announce today?

In today's release, Osteopore advised it has signed an agreement for an $18.7 million project with two major research institutes in Singapore.

The company will work with the National Dental Research Institute and the Agency for Science, Technology and Research to develop jaw implants.

As part of the study, the company said it would test some of its patented products for potential use in dental applications.

Osteopore would use the research results to help develop jaw implants that would ultimately simplify future dental procedures.

If this research proved successful, the company said it could tap into a global market worth an estimated $1.26 billion.

Osteopore will commit $1.8 million towards the project over three years.

Management comment

Welcoming the announcement, Osteopore CEO Goh Seng said:

We are very thankful to participate and lead this grant and for the support of all the institutions involved in this research.

We strongly believe in developing and commercialising regenerative technologies for the well-being of patients.

Company chair Mark Leong added:

We are constantly developing new and better applications for our technology as well as growing addressable markets. This partnership project is a significant step for Osteopore.

Osteopore share price snap shot

Osteopore investors have experienced a turbulent year in 2021, falling 50% since January. In the past 12 months, the Osteopore share price has also dropped by around 50%.

Osteopore reached a yearly high of 53 cents in April, before dropping to a yearly low of 20 cents last week.

The company's total market capitalisation is around $30 million, based on the current share price.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Two colleagues looking at a graph and comparing share prices.
Healthcare Shares

CSL shares: Buy, hold, or sell?

The shares have recovered sharply, so I wanted to see whether the valuation still stacks up.

Read more »

Two colleagues looking at a graph and comparing share prices.
Healthcare Shares

Telix vs Clinuvel Pharmaceuticals: Which ASX healthcare share deserves your next $1,000 of investment capital?

We compare Telix and Clinuvel Pharmaceuticals on valuation, dividends, and momentum—which ASX healthcare stock looks more compelling now?

Read more »

Numerous Australian dollar notes laid out.
Healthcare Shares

I'd buy 6,462 shares of this ASX stock to aim for $200 a month of passive income

This business can provide very healthy dividends.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

UBS thinks Telix Pharmaceuticals shares will go how high?

Good news out of the US has led to a share price target upgrade.

Read more »

Scientist taking down notes from a tablet, with two other scientists working in the background.
Healthcare Shares

Healius vs Australian Clinical Labs: Which ASX pathology share wins?

Healius and Australian Clinical Labs are both top pathology providers, but one stands out for profits, dividends, and recent momentum.

Read more »

Doctor looks at a graph on a tablet.
Healthcare Shares

Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?

Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my…

Read more »

A doctor looks unsure.
Healthcare Shares

CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October?

Can the CSL share price rebound keep going?

Read more »

Two doctors having a discussion about a patient diagnosis, holding digital tablet.
Healthcare Shares

Are CSL shares a buy after its big news?

I look at what CSL’s latest drug development deal could mean for the healthcare giant’s long-term growth.

Read more »